Open AccessLinezolid as treatment for pulmonary Mycobacterium avium disease
Author(s) -
Devyani Deshpande,
Shashikant Srivastava,
Jotam G. Pasipanodya,
Tawanda Gumbo
Publication year - 2017
Publication title -
journal of antimicrobial chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.124
H-Index - 194
eISSN - 1460-2091
pISSN - 0305-7453
DOI - 10.1093/jac/dkx304
Subject(s) - linezolid , pharmacokinetics , medicine , minimum inhibitory concentration , pharmacodynamics , antibiotics , antibacterial agent , pulmonary disease , microbiology and biotechnology , pharmacology , mycobacterium avium complex , biology , bacteria , staphylococcus aureus , vancomycin , genetics
To identify the pharmacokinetic/pharmacodynamic parameters and exposures of linezolid in the treatment of pulmonary Mycobacterium avium complex (MAC) disease.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom